Jones et al. Non-smokers, normal BMI, and current drinkers! with AxSpA more likely to respond to TNFi. @RheumNow #ACR22 Abstr#1510 https://t.co/inCz2sAyj5 https://t.co/K27ptuLV7Y

• Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of T…

Everyday heroes during #COVID19 Keynote @ACRheum Health care workers who were minorities disproportionately died in the early days of the pandemic. Can’t be all SES as risk but maybe ‘status’ as first line workers. Remember them #ACRBest #ACR22 @RheumNow @AbrahamVerghese 🙏🏻 https://t.co/AjkV5wDVEu

Only 4 minutes to discuss adherence in #SLE. Implementation of discussion if <80% of meds filled. Academic docs - 20/24 used + reinforcement, validated in 17 Pts, 11/24 asked open ended ?s. Pts thought it was right timing. ?does it change behaviour- ? Abst0063 @RheumNow #ACR22 https://t.co/UQbRgw5Emj

Sunday: ACR 2022 Daily Recap https://t.co/9naWAYwJIV

• https://twitter.com/i/broadcasts/1ZkJzXgkMqoKv

#ClinicalPearl woman with non-radiographic axSpA have LESS inactive disease vs MEN but NOT true if radiographic axSpA. 5 yr global study N=2633, independent of TNFi use - not sure why there are differences. Misclassification dx- unlikely. abst#1614 #ACR22 #ACRBest @RheumNowNews https://t.co/coNjwHOkLP

Lifetime career achievement ✔️ - first author of a paper in ACR year in review #ACR22 https://t.co/M5GrOcWY5X

• https://twitter.com/rheum_cat/status/1591452540067090434

$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v

• Health System Improvement in Inpatient ANA and Serologic Test Utilization - ACR…

Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7

• Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh…

@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22 @jhrheumatology @JHRheumFellows https://t.co/aSRHiJoIkE

Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H

• Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Populat…

2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. #ACR22 @RheumNow https://t.co/sLwoxeCR3y https://t.co/47wpWXF1W7

• Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmun…

HCQ does not prevent RA in CCP+ pts w/out clinical arthritis! Stop RA: RCT HCQ vs. PBO in pts at-risk Interim analysis 140+ pts RA development HCQ 34% vs. PBO 36% Trial interrupted as met futility criteria. https://t.co/n31OmsjLhM Abs#1604 #ACR22 @RheumNow #ACRBest https://t.co/NVYS8kB5to

• Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthri…

2022 ACR G/L for Integrative RA Intervent #ACR22 1 strong rec: consistent exercisee 27 conditional recs: Rehab, Mediterr diet, against other diets, self-mgmt/CBT/acupunct Conditional against electrotherapy, chiropractor No rec for diet supplem BMI, 🚬: no RA spec recomm @RheumNow https://t.co/cVFr6beQuJ

Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for dialysis 75.6% vs 16.7%, p=0.023. No effect on overall survival. 5-year mortality 70%, 1 year mortality 58%. @RheumNow #ACR22 Abstr#1530 https://t.co/cdYhEtqcHT https://t.co/lDWJto1cF0

• Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortali…